Oveporexton treats more than symptoms, restores orexin signaling
— Oveporexton treats more than symptoms, restores orexin signaling
by Nicole Lou, Senior Staff Writer, MedPage Today
August 6, 2026
• 2 min read
The FDA approved oveporexton (Orzeyful) for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults, the agency announced Wednesday.
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
The U.S. Food and Drug Administration on Wednesday approved the first drug to treat a "full range" of narcolepsy type 1 symptoms…
Takeda's Orzeyful wins FDA approval as the first full-symptom narcolepsy type 1 drug, kicking off an orexin agonist race with…
After coming up short in trials with two orexin type 2 receptor (OX2R) selective agonists, Takeda has scored with oveporexton,
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with…
An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that…
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
FDA approves new drug for narcolepsy type 1 symptoms - UPI.com
Let the orexin market begin: Takeda snags FDA approval for narcolepsy type 1 drug
Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful
Takeda approval ushers in new wave of sleep drugs
Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
China Beats U.S. in Approving Takeda’s Breakthrough Narcolepsy Drug
Svolta contro la narcolessia, negli Usa la prima cura che agisce sulla causa della malattia
Symptoms improved within first week: FDA approves new ADHD drug for children, adults
In a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels
